Deepa Jeyakumar

2.3k total citations
54 papers, 540 citations indexed

About

Deepa Jeyakumar is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Deepa Jeyakumar has authored 54 papers receiving a total of 540 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 23 papers in Genetics and 15 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Deepa Jeyakumar's work include Chronic Lymphocytic Leukemia Research (22 papers), Acute Myeloid Leukemia Research (20 papers) and Acute Lymphoblastic Leukemia research (15 papers). Deepa Jeyakumar is often cited by papers focused on Chronic Lymphocytic Leukemia Research (22 papers), Acute Myeloid Leukemia Research (20 papers) and Acute Lymphoblastic Leukemia research (15 papers). Deepa Jeyakumar collaborates with scholars based in United States, United Kingdom and Thailand. Deepa Jeyakumar's co-authors include Michael H. Malim, William J. Swiggard, Una O’Doherty, Susan O’Brien, Una O’Doherty, Terrence Bradley, David A. Sallman, Paresh Vyas, Suman Kambhampati and Adam S. Asch and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Virology.

In The Last Decade

Deepa Jeyakumar

42 papers receiving 537 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Deepa Jeyakumar United States	10	211	174	143	139	122	54	540
Angharad E. Fenton-May United Kingdom	8	223 1.1×	128 0.7×	228 1.6×	122 0.9×	92 0.8×	10	525
Katie Matthews United States	13	142 0.7×	175 1.0×	254 1.8×	87 0.6×	116 1.0×	20	617
Evelien Naessens Belgium	13	278 1.3×	62 0.4×	294 2.1×	118 0.8×	213 1.7×	26	620
Laure Moutouh–de Parseval United States	8	160 0.8×	157 0.9×	138 1.0×	64 0.5×	255 2.1×	8	523
Sofiya A. Galkina United States	8	202 1.0×	49 0.3×	354 2.5×	174 1.3×	110 0.9×	9	650
Shigehisa Mori Japan	13	94 0.4×	82 0.5×	105 0.7×	71 0.5×	123 1.0×	40	625
Andréa Monteiro Tarragô Brazil	15	56 0.3×	83 0.5×	117 0.8×	30 0.2×	91 0.7×	45	452
Alessandra Sottini Italy	11	155 0.7×	53 0.3×	498 3.5×	84 0.6×	57 0.5×	17	675
Kara B. Anthony United States	9	173 0.8×	49 0.3×	150 1.0×	84 0.6×	78 0.6×	10	462
Cristina Gálvez Spain	13	318 1.5×	22 0.1×	149 1.0×	207 1.5×	149 1.2×	20	512

Countries citing papers authored by Deepa Jeyakumar

Since Specialization

Citations

This map shows the geographic impact of Deepa Jeyakumar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deepa Jeyakumar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deepa Jeyakumar more than expected).

Fields of papers citing papers by Deepa Jeyakumar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deepa Jeyakumar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deepa Jeyakumar. The network helps show where Deepa Jeyakumar may publish in the future.

Co-authorship network of co-authors of Deepa Jeyakumar

This figure shows the co-authorship network connecting the top 25 collaborators of Deepa Jeyakumar. A scholar is included among the top collaborators of Deepa Jeyakumar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deepa Jeyakumar. Deepa Jeyakumar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jeyakumar, Deepa, Kiran Naqvi, Benjamin J. Lee, et al.. (2025). Narsoplimab for Refractory Transplantation-Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). Transplantation and Cellular Therapy. 31(2). S378–S379. 1 indexed citations

Kongtim, Piyanuch, et al.. (2025). Budesonide, Added to PTCy‐Based Regimen, for Prevention of Acute GI GVHD After Allogeneic Stem Cell Transplantation. American Journal of Hematology. 100(3). 383–392.

Jonas, Brian A., Peter Curtin, Gary J. Schiller, et al.. (2025). A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503). Leukemia Research. 155. 107717–107717.

Mannis, Gabriel N., Nikolai A. Podoltsev, Deepa Jeyakumar, et al.. (2025). Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy. Blood. 146(Supplement 1). 1645–1645.

Brém, Elizabeth, et al.. (2024). A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. PubMed. 1(4). 100036–100036. 3 indexed citations

Lee, Benjamin J., Hannah Nam, Deepa Jeyakumar, et al.. (2024). Persistent Impairment in Immune Reconstitution and Worse Survival Outcomes in Allogeneic Stem Cell Transplantation Patients with Early Coronavirus Disease 2019 Infection. Transplantation and Cellular Therapy. 30(8). 816.e1–816.e10. 2 indexed citations

Oliai, Caspian, Sunmin Park, Brian A. Jonas, et al.. (2024). CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial. Leukemia & lymphoma. 66(4). 773–779.

Lee, Benjamin J., Julie Smith, Hannah Nam, et al.. (2024). Extending duration of letermovir prophylaxis in haploidentical stem cell transplantation. Haematologica. 109(11). 3806–3810. 1 indexed citations

Lee, Benjamin J., et al.. (2024). Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) Results in Higher Remission Rates over Conventional 7+3 Chemotherapy without Increased Toxicity in Newly Diagnosed Acute Myeloid Leukemia. Blood. 144(Supplement 1). 1517–1517.

10.

Jonas, Brian A., Jing‐Zhou Hou, Gail J. Roboz, et al.. (2023). A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia. Hematological Oncology. 41(4). 743–752. 12 indexed citations

11.

Jeyakumar, Deepa, et al.. (2023). Budesonide Added to Post-Transplantation Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease. Blood. 142(Supplement 1). 2192–2192.

12.

Sekeres, Mikkael A., Pau Montesinos, Jan Novák, et al.. (2023). Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. Leukemia. 37(10). 2017–2026. 15 indexed citations

13.

Lee, Benjamin J., Hannah Nam, Emily Blodget, et al.. (2023). Once-Daily Foscarnet Is Effective for Human Herpesvirus 6 Reactivation after Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 29(6). 397.e1–397.e6. 7 indexed citations

14.

Daver, Naval, Paresh Vyas, Suman Kambhampati, et al.. (2022). AML-464 Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results. Clinical Lymphoma Myeloma & Leukemia. 22. S253–S254. 5 indexed citations

15.

Advani, Anjali S., Anna Moseley, Kristen M. O’Dwyer, et al.. (2021). A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations). Blood. 138(Supplement 1). 3397–3397. 9 indexed citations

16.

Schwartz, Marc S., Lloyd E. Damon, Deepa Jeyakumar, et al.. (2019). Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504. Blood. 134(Supplement_1). 3880–3880. 10 indexed citations

17.

Zhang, Kuixing, et al.. (2018). Prolymphocytic transformation of lymphoplasmacytic lymphoma: an extremely unusual event. Human Pathology. 90. 106–110. 2 indexed citations

18.

Jerkins, James H., et al.. (2016). A Patient with Supraclavicular Lymphadenopathy and Anterior Mediastinal Mass Presenting as a Rare Case of Composite Lymphoma: A Case Report and Literature Review. Case Reports in Oncology. 9(3). 854–860. 3 indexed citations

19.

Swiggard, William J., et al.. (2004). Long HIV Type 1 Reverse Transcripts Can Accumulate Stably within Resting CD4 ⁺ T Cells While Short Ones Are Degraded. AIDS Research and Human Retroviruses. 20(3). 285–295. 44 indexed citations

20.

Jeyakumar, Deepa, et al.. (1994). Huntington disease: report of first case documented in Malaysia.. PubMed. 49(3). 297–300. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact